Targeted nanotherapeutics in cancer
Farooq A ShiekhAvalon University School of Medicine, Curaçao, Netherlands AntillesCancer is not one, but many heterogeneous diseases1 with complex genetic and epigenetic alterations2,3 that annually afflict millions of people worldwide. Despite the progress in understanding the molecular...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3bbd4243bc3d460fa56bf2b35fead51a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3bbd4243bc3d460fa56bf2b35fead51a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3bbd4243bc3d460fa56bf2b35fead51a2021-12-02T04:21:22ZTargeted nanotherapeutics in cancer1178-2013https://doaj.org/article/3bbd4243bc3d460fa56bf2b35fead51a2014-03-01T00:00:00Zhttp://www.dovepress.com/targeted-nanotherapeutics-in-cancer-a16248https://doaj.org/toc/1178-2013 Farooq A ShiekhAvalon University School of Medicine, Curaçao, Netherlands AntillesCancer is not one, but many heterogeneous diseases1 with complex genetic and epigenetic alterations2,3 that annually afflict millions of people worldwide. Despite the progress in understanding the molecular mechanics of cancer,4 its treatment has remained essentially unchanged and the death rates almost remain as they were 6 decades ago.5,6 In the past, the outstanding failure to deliver effective treatment to patients was a result of the inability to get enough of the right drug to the right place; however, the scenario has started to change substantially with the advent of new "targeted" cancer therapies.7–10Shiekh FADove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 1627-1628 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Shiekh FA Targeted nanotherapeutics in cancer |
| description |
Farooq A ShiekhAvalon University School of Medicine, Curaçao, Netherlands AntillesCancer is not one, but many heterogeneous diseases1 with complex genetic and epigenetic alterations2,3 that annually afflict millions of people worldwide. Despite the progress in understanding the molecular mechanics of cancer,4 its treatment has remained essentially unchanged and the death rates almost remain as they were 6 decades ago.5,6 In the past, the outstanding failure to deliver effective treatment to patients was a result of the inability to get enough of the right drug to the right place; however, the scenario has started to change substantially with the advent of new "targeted" cancer therapies.7–10 |
| format |
article |
| author |
Shiekh FA |
| author_facet |
Shiekh FA |
| author_sort |
Shiekh FA |
| title |
Targeted nanotherapeutics in cancer |
| title_short |
Targeted nanotherapeutics in cancer |
| title_full |
Targeted nanotherapeutics in cancer |
| title_fullStr |
Targeted nanotherapeutics in cancer |
| title_full_unstemmed |
Targeted nanotherapeutics in cancer |
| title_sort |
targeted nanotherapeutics in cancer |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/3bbd4243bc3d460fa56bf2b35fead51a |
| work_keys_str_mv |
AT shiekhfa targetednanotherapeuticsincancer |
| _version_ |
1718401304745738240 |